Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Institutions
Pharmaceutical companies
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Loading…

Medicines
Netherlands
Atogepant

CBG-MEB 2023

Atogepant

AQUIPTA 10 mg tabletten

TabletNetherlandsAuthorisedAuthorised 11 Aug 2023

Product informationAsk Osler about it

On this page

In other countries
Documents
Sources and licences

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

AquiptaEuropean UnionAuthorised

AquiptaBrazil · Abbvie Farmacêutica Ltda.Same brand
Aquipta 10 MG ComprimidosSpain · 10 mg · comprimido · Abbvie Deutschland Gmbh & Co. KgSame brand
Aquipta 60 MG ComprimidosSpain · 60 mg · comprimido · Abbvie Deutschland Gmbh & Co. KgSame brand
AquiptaEuropean Union · AbbVie Deutschland GmbH & Co. KGSame brand
AquiptaCroatiaSame brand
AquiptaItaly · Compressa · Abbvie Deutschland GMBH & Co. KGSame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

🇷🇸

Aquipta®Serbia · 60mg · tableta · Abbvie D.O.O. Beograd

Same brand

🇷🇸Aquipta®Serbia · 10mg · tableta · Abbvie D.O.O. BeogradSame brand

🇸🇬Aquipta Tablet 10MGSingapore · 10.0mg · tablet · Abbvie Pte. LTD.Same brand

🇸🇬Aquipta Tablet 60MGSingapore · 60.0mg · tablet · Abbvie Pte. LTD.Same brand

🇨🇦QuliptaCanada · 60 MG · Tablet · Abbvie CorporationSame form

🇨🇦QuliptaCanada · 10 MG · Tablet · Abbvie CorporationSame form

🇨🇦QuliptaCanada · 30 MG · Tablet · Abbvie CorporationSame form

🇺🇸QuliptaUnited States · 10MG, 30MG, 60MG · tablet · AbbvieSame form

Documents

The official texts, at the regulator.

Summary of product characteristicsCBG-MEB
Register entryCBG-MEB

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Atogepant
Dosage form: Tablet
Route: Oraal gebruik
Register: Netherlands (CBG-MEB)
Status: Authorised
Status in the register: Ingeschreven
Authorised: 11 Aug 2023
Registration: EU/1/23/1750
Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
ATC code: N02CD07
Group: Nervous system
Procedure: EU centralised
Supply: Uitsluitend recept
EMA product number: EMEA/H/C/005871
EU number: EU/1/23/1750